PCVX vs. RVMD, EXEL, IBRX, RGEN, HALO, QGEN, CRSP, KRYS, IMVT, and IOVA
Should you be buying Vaxcyte stock or one of its competitors? The main competitors of Vaxcyte include Revolution Medicines (RVMD), Exelixis (EXEL), ImmunityBio (IBRX), Repligen (RGEN), Halozyme Therapeutics (HALO), Qiagen (QGEN), CRISPR Therapeutics (CRSP), Krystal Biotech (KRYS), Immunovant (IMVT), and Iovance Biotherapeutics (IOVA). These companies are all part of the "biological products, except diagnostic" industry.
Revolution Medicines (NASDAQ:RVMD) and Vaxcyte (NASDAQ:PCVX) are both mid-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their community ranking, dividends, profitability, media sentiment, institutional ownership, risk, analyst recommendations, earnings and valuation.
In the previous week, Revolution Medicines had 7 more articles in the media than Vaxcyte. MarketBeat recorded 10 mentions for Revolution Medicines and 3 mentions for Vaxcyte. Revolution Medicines' average media sentiment score of 0.67 beat Vaxcyte's score of 0.35 indicating that Vaxcyte is being referred to more favorably in the news media.
Revolution Medicines' return on equity of -32.04% beat Vaxcyte's return on equity.
Revolution Medicines currently has a consensus price target of $41.20, indicating a potential upside of 7.54%. Vaxcyte has a consensus price target of $78.50, indicating a potential upside of 17.53%. Given Revolution Medicines' higher probable upside, analysts plainly believe Vaxcyte is more favorable than Revolution Medicines.
Vaxcyte has lower revenue, but higher earnings than Revolution Medicines. Vaxcyte is trading at a lower price-to-earnings ratio than Revolution Medicines, indicating that it is currently the more affordable of the two stocks.
Revolution Medicines has a beta of 1.46, meaning that its share price is 46% more volatile than the S&P 500. Comparatively, Vaxcyte has a beta of 0.94, meaning that its share price is 6% less volatile than the S&P 500.
Revolution Medicines received 31 more outperform votes than Vaxcyte when rated by MarketBeat users. Likewise, 68.13% of users gave Revolution Medicines an outperform vote while only 67.39% of users gave Vaxcyte an outperform vote.
94.3% of Revolution Medicines shares are owned by institutional investors. Comparatively, 96.8% of Vaxcyte shares are owned by institutional investors. 8.5% of Revolution Medicines shares are owned by company insiders. Comparatively, 3.1% of Vaxcyte shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Summary
Revolution Medicines beats Vaxcyte on 11 of the 17 factors compared between the two stocks.
Get Vaxcyte News Delivered to You Automatically
Sign up to receive the latest news and ratings for PCVX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PCVX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
